Trifluridine/tipiracil (TAS-102) is a new oral combination therapy approved by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer who are refractory to or intolerant of standard chemotherapy. This agent consists of a thymidine-based nucleoside analogue (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil), which is included to reduce the degradative breakdown of trifluridine. In the phase III Randomized, double-blind, phase III Study of TAS-102 plus best supportive care [BSC] versus placebo plus BSC in patients with metastatic colorectal cancer [CRC] refractory to standard chemotherapies (RECOURSE) trial, trifluridine/tipiracil showed significant improvement in overall survival compared with placebo. Trifluridine/tipiracil is administered at a 35 mg/m 2 dose orally twice daily in a 28-day cycle consisting of 5 treatment days/2 rest days for 2 weeks followed by a rest period of 2 weeks. Because trifluridine/tipiracil is a completely oral chemotherapy regimen, patient adherence to treatment is an important consideration. It is also critical to have strategies in place for managing toxicities, because side effects might have a negative effect on patient adherence. The most frequent adverse events reported in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in the phase III RECOURSE trial were myelosuppression, nausea/vomiting, diarrhea, decreased appetite, and fatigue. In this review we aim to provide clinicians with practical recommendations for facilitating patient adherence to oral chemotherapy, managing trifluridine/tipiracil dosing, and address the most common adverse events in patients who receive trifluridine/tipiracil therapy.
Introduction
An estimated 135,000 Americans will be diagnosed with colorectal cancer (CRC) in 2017, and nearly 50,000 will die from this disease. 1 CRC is the third most common cancer diagnosis for men as well as women in the United States and the second most common cause of cancer death for both sexes. 1 Despite a steady decline in CRC-associated mortality over the past 2 decades, the 5-year survival rate for patients diagnosed with advanced, metastatic disease remains low (8%-12%). 1 There is clearly a significant need for well tolerated, effective treatment options for patients with metastatic CRC (mCRC) who are refractory to standard chemotherapy. Treatment options for patients with mCRC whose disease progresses beyond first-and second-line therapy remain limited, and they are determined by the previous treatment regimens received by the patient. 2 Regorafenib is a small-molecule multikinase inhibitor, which is currently approved for the treatment of patients with mCRC in the third-line or later setting. 2 A randomized, double-blind, placebocontrolled phase III study of regorafenib plus best supportive care
[BSC] versus placebo plus BSC in patients with metastatic colorectal cancer [CRC] who have progressed after standard therapy (CORRECT) trial was a randomized phase III study that compared regorafenib with placebo in patients with mCRC who had received all standard therapies (n ¼ 760); this study showed significant improvement in median overall survival (OS) in the regorafenib arm compared with the placebo arm (6.4 vs. 5.0 months; hazard ratio [HR] , 0.77; 95% confidence interval [CI] , 0.64-0.94; 1-sided P ¼ .0052). 3 Treatment-related adverse events (AEs) were observed in 465 patients (93%) in the regorafenib arm and in 154 patients (61%) in the placebo arm. The most common Grade 3 AEs in patients who received regorafenib were hand-foot skin reaction (83 patients, 17%), fatigue (48 patients, 10%), diarrhea (36 patients, 7%), hypertension (36 patients, 7%), and skin rash (29 patients, 6%). These AEs might necessitate dose modifications and/or permanent discontinuation of the drug.
Trifluridine/Tipiracil (TAS-102)
Trifluridine/tipiracil (TAS-102) is a new oral fluoropyrimidine therapy approved by the national health authorities in the United States, Europe, and Japan for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an antivascular endothelial growth factor biologic product, and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, if rat sarcoma viral oncogene homologue wild type. Trifluridine is a thymidine-based nucleoside analogue that is metabolized to the triphosphate metabolite, which is then incorporated into DNA, resulting in inhibition of DNA synthesis and function. The trifluridine monophosphate inhibits thymidylate synthase (TS), which is the key enzyme that provides for the sole intracellular source of thymidylate, an essential nucleotide precursor for DNA biosynthesis. In contrast to the 5-fluorouracil (5-FU) metabolite fluorodeoxyuridine monophosphate, trifluridine monophosphate has been shown to be a much weaker inhibitor of TS, and it is believed that TS inhibition does not play a major role in the biological activity of the molecule. Tipiracil is a thymidine phosphorylase (TP) inhibitor, which inhibits trifluridine degradative metabolism by TP; this inhibition leads to enhanced activation of trifluridine to the monophosphate and triphosphate cytotoxic metabolites. 5, 6 The mechanism of action of trifluridine/tipiracil is, therefore, somewhat different from that of 5-FU, a fluoropyrimidine base analogue that has been the foundation of mCRC treatment for approximately the past 50 years. 7, 8 The main cytotoxic effect of 5-FU is primarily mediated through inhibition of TS, which leads to inhibition of DNA synthesis ( Figure 1 ). [7] [8] [9] In addition, 5-FU also exerts its biological activity through incorporation of the 5-FU metabolite fluorodeoxyuridine triphosphate into DNA, leading to inhibition of DNA synthesis and function, and through incorporation of the 5-FU metabolite fluorouridine triphosphate into RNA, resulting in inhibition of RNA synthesis and function. 7 The clinical efficacy and safety of trifluridine/tipiracil in patients with mCRC refractory or intolerant to standard therapies were evaluated in the international, randomized phase III Randomized, double-blind, phase III Study of TAS-102 plus best supportive care [BSC] versus placebo plus BSC in patients with metastatic colorectal cancer [CRC] refractory to standard chemotherapies (RECOURSE) trial (n ¼ 800). 10 The enrollment criteria for RECOURSE included 2 previous lines of standard chemotherapy, which included previous fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab. 10 Patients with Kirsten rat sarcoma viral oncogene homologue wild type tumors were also required to have previously received an anti-EGFR antibody (either cetuximab or panitumumab). 10 10 Of note, despite the improvements in OS and PFS, the objective response rate (complete response or partial response) was low at only 1.6% (n ¼ 8/502) with Figure 1 The Mechanisms of Action for TAS-102 and 5-FU trifluridine/tipiracil compared with 0.4% (n ¼ 1/258) in the placebo arm (P ¼ .29). With respect to safety profile, treatment with trifluridine/tipiracil (n ¼ 533) was associated with a higher frequency of Grade 3 AEs compared with those in the placebo group (69% vs. 52%). 10 The incidence of Grade 3 neutropenia was 38% (n ¼ 200/528) in patients treated with trifluridine/tipiracil, but there was a relatively low incidence of febrile neutropenia (20 patients, 4%). In comparison, no cases of Grade 3 neutropenia were observed in the placebo group. 10 There was 1 treatment-related death due to septic shock. 10 The trifluridine/tipiracil group had a higher incidence of Grade 3 anemia (18% vs. 3%) and Grade 3 thrombocytopenia (5% vs. <1%) compared with the placebo group and higher rates of Grade 3 nausea (2% vs. 1%), vomiting (2% vs. <1%), and diarrhea (3% vs. <1%). 10 There were no clinically meaningful differences between the treatment groups in the percentage of patients with Grade 3 hepatic or renal laboratory abnormalities, decreased appetite, stomatitis, hand-foot syndrome, or cardiac ischemia.
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Trifluridine/Tipiracil Dosing
The recommended dosing regimen of trifluridine/tipiracil is 35 mg/m 2 orally twice daily on days 1 through 5 and days 8 through 12 of each 28-day cycle. 11 Each treatment cycle is followed by a 2-week rest period, the goal of which is to allow for blood counts to recover before the next treatment cycle is administered. In the case of a missed dose, patients are advised to take the next dose as scheduled without attempting to make up for the missed dose.
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In general, no dose adjustments are recommended for patients with mild hepatic impairment (total bilirubin [TB] less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase [AST] > ULN; or TB < 1-1.5 times the ULN and any AST). Patients with moderate (TB < 1.5-3 times the ULN and any AST) or severe hepatic impairment (TB > 3 times the ULN and any AST) were not enrolled in the RECOURSE trial, 11 so caution is required when using trifluridine/tipiracil in the setting of moderate to severe hepatic dysfunction. In Europe, administration of the drug is not recommended in patients with moderate or severe hepatic dysfunction. 12 With respect to renal dysfunction, no dose adjustments are recommended for patients with mild renal impairment (creatinine clearance [CrCL] of 60-89 mL/min; Table 1 ). Patients with moderate renal impairment (CrCL of 30-59 mL/min) might experience an increased risk of toxicity, which would then require dose modifications. 11 Patients with severe renal impairment (CrCL < 30 mL/min) were not enrolled in the RECOURSE trial, and caution is recommended when using trifluridine/tipiracil in this cohort of patients. 11 In Europe, administration is not recommended for this group of patients. 12 At the present time, organ dysfunction studies are ongoing in the United States to determine how best to dose trifluridine/tipiracil in patients with hepatic and/or renal dysfunction.
Association Between Onset of Neutropenia and Survival
The potential predictive value of neutropenia caused by cytotoxic drugs has been reported in several cancer types. [13] [14] [15] [16] A post hoc analysis of RECOURSE was performed to determine the potential correlation between onset of Grade 3 neutropenia and clinical benefit. 17 Of 533 patients who received trifluridine/tipiracil, 75
(14%) developed Grade 3 neutropenia in treatment cycle 1, 86 (16%) in cycle 2, and 39 (7%) in cycle 3. 17 Onset of Grade 3 neutropenia during any cycle was associated with longer median OS and PFS compared with no onset of neutropenia.
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This association between the occurrence of neutropenia after trifluridine/tipiracil and survival benefit has been reported by other investigators. 18, 19 The RECOURSE data indicated that such survival benefit occurred regardless of whether the initial onset of neutropenia occurred after cycle 1, cycle 2, or with later cycles of therapy. However, this observation does not support that Grade 3 neutropenia could be aimed or tolerated to improve survival during TAS-102 therapy. In general, neutropenia is a manageable treatment-related toxicity. Clinicians should use caution when considering dose reductions of trifluridine/tipiracil in patients who present with mild neutropenia. In this situation, it might be prudent to delay treatment, because dose reductions might negatively affect the clinical efficacy of the drug whereas a dose delay might not have the same negative consequence. It should also be noted that, as was observed in the RECOURSE study, Grade 3 neutropenia might occur for the first time after cycle 1. 
Oral Chemotherapy: Adherence and Other Considerations
Trifluridine/tipiracil is a completely oral chemotherapy regimen. There is now a growing body of evidence showing that most patients prefer oral chemotherapy, citing convenience, problems with intravenous access or needles, and a better chemotherapy-taking environment as their main reasons. [20] [21] [22] [23] However, despite this preference for oral chemotherapy, patients are clearly not willing to compromise clinical benefit in terms of lower response rate or shorter duration of response. Moreover, patients and their caregivers might not be sufficiently prepared to play a more active role in their chemotherapy by taking greater responsibility for managing dosing schedules, toxicities, and other considerations associated with an oral regimen. 20 Patients might also have the misperception that, compared with parenteral chemotherapy, oral chemotherapy is safer and associated with fewer toxicities. 20 
Adherence to Oral Chemotherapy
It is important to consider adherence when assessing whether a patient is a potential candidate for oral chemotherapy. 20 Studies on adherence to oral chemotherapy in adults have shown variable results, with rates of adherence and persistence ranging from < 20% to 100%. 24, 25 Several factors might influence patient adherence, with perhaps the most important one being management of the symptoms and/or side effects of therapy. 24, 26 One potential advantage to trifluridine/tipiracil therapy is the relatively low number of drug-drug interactions; this results from the fact that neither trifluridine nor tipiracil is metabolized by the liver P450 enzymes. 11 However, the rate and extent of absorption of trifluridine/tipiracil are reduced by food, and the recommendation is for this agent to be taken within 1 hour after a meal. 11 A pharmacokinetic study on food effects in patients with solid tumors (n ¼ 16) reported that the maximum concentration (C max ) of trifluridine was decreased by approximately 40% when trifluridine/tipiracil was administered after a high-fat, high-calorie meal (110 kcal of protein, 180 kcal of carbohydrates, and 360-430 kcal of fat) with no associated change in systemic drug exposure (area under the curve of trifluridine). 27 This decrease in C max of trifluridine was believed to be beneficial in reducing the risk of myelosuppression, because a significant correlation between C max of trifluridine and decreased neutrophil count was observed. 27 Patients who receive trifluridine/ tipiracil should be encouraged to speak with physicians, nurses, and/ or dietitians/nutritionists for counseling on nutrition and managing eating problems. 28 However, on the basis of the clinical data generated thus far, it appears that patients do not need to be concerned about the particular type of food content or diet because they do not have a critical effect on absorption and bioavailability. Furthermore, it is especially critical for patients and their caregivers to be educated on when to take trifluridine/tipiracil, with the recommendation being that the drug should be taken within 1 hour after completion of morning and evening meals.
Patient and Caregiver Education
One of the potential drawbacks with oral chemotherapy is that there are fewer required visits to the clinic than with intravenous chemotherapy, which then provides a reduced number of opportunities for patient education, counseling, and communication. 20, 26 Therefore, communication with the patient before the initiation of oral chemotherapy is viewed as a critical issue in maintaining patient adherence. Oncologists, midlevel providers, and nurses should engage in a thoughtful discussion with patients and caregivers about the patient's commitment to adherence. They must also discuss the possibility of any socioeconomic, psychosocial, financial, or other barriers that might prevent the patient from obtaining or taking the drug as prescribed. 20, 26 An important financial issue relates to the oral chemotherapy parity law, which states that oral chemotherapy should be covered to the same extent as intravenous chemotherapy.
Although there is a federal law that mandates equal coverage for oral chemotherapy, it is currently up to the individual state legislatures to ensure that this law is enforced. To date, 6 US states have not approved parity for oral chemotherapy, which might place a significant financial burden on patients.
Patients should receive written educational material about the regimen, the schedule of appointments, and instructions for addressing toxicities, including emergency contact information and a clear definition of the circumstances for which the patient should contact the oncologist or another health care provider. 26 It is also recommended that patients receive written or electronic educational materials on safe handling, administration, and disposal of the drug and how to address the issue of missed doses. 26 Information about supportive care and the possibility of any drug-drug or drug-food interactions should also be included, if relevant. 26 Depending on the individual patient's ability to manage his or her own therapy, the patient's family and/or caregivers should also receive specific education about the use of oral chemotherapy. 26 It is critically important to tailor educational materials to a patient's reading level and to use patient feedback to gauge the patient's level of understanding and involvement. 26 Patient adherence and the occurrence of any potential adverse effects should be closely monitored at each visit.
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Adverse Events and Management
It is important for oncologists to know which AEs to expect in patients with mCRC who are receiving trifluridine/tipiracil and to discuss these anticipated AEs with patients. In the RECOURSE trial, hematologic AEs as well as nausea, diarrhea, vomiting, decreased appetite, and fatigue were most commonly observed in the trifluridine/tipiracil group (Table 2) . 10 These AEs most often started during the first cycle of dosing. 29 The recommended strategies for managing the most common hematologic and nonhematologic AEs in patients receiving trifluridine/tipiracil therapy are discussed in the following sections ( Figure 2 ).
Hematologic AEs
Myelosuppression is one of the main toxicities observed with trifluridine/tipiracil. In the RECOURSE trial, the incidence of Grade 3 neutropenia was 38% in patients treated with trifluridine/tipiracil, but there was a relatively low incidence of febrile neutropenia (4%). 10 The trifluridine/tipiracil group had a higher incidence of Grade 3 anemia (18% vs. 3%) and Grade 3 thrombocytopenia (5% vs. < 1%) compared with the placebo group. 10 Patients should have complete blood counts before receiving the drug and on day 15 of each 28-day cycle.
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Neutropenia. In the event of Grade 4 neutropenia (absolute neutrophil count [ANC] < 500/mm 3 ) within a treatment cycle, the dose of trifluridine/tipiracil should be held until the ANC increases to 1500/mm 3 ( Figure 2A) . 11 If the delay is longer than 1 week, the dose of trifluridine/tipiracil in the next cycle should be reduced by 5 mg/m 2 per dose from the previous dose level (Table 3) . 4, 11 If febrile neutropenia occurs, the dose of trifluridine/tipiracil should be held until the episode of febrile neutropenia is completely resolved, and the drug dose in the next cycle should be reduced by 5 mg/m 2 per dose from the previous dose level (Table 3) .
Prophylactic administration of myeloid growth factors is recommended to prevent the development of febrile neutropenia in patients who receive myelosuppressive chemotherapy. 30, 31 The risk of febrile neutropenia is on the basis of the patient's cancer, chemotherapy regimen, and patient factors such as age, performance or nutritional status, renal and liver function, previous chemotherapy, preexisting neutropenia or infection, and recent surgery or open wounds. 30, 31 In general, myeloid growth factors are recommended for patients with a high risk of febrile neutropenia (> 20% risk), and they should be considered for patients with an intermediate risk of febrile neutropenia (10%-20% risk). 30, 31 Currently, the myeloid growth factors approved by the US Food and Drug Administration are the granulocyte colony-stimulating factors (G-CSFs) filgrastim, filgrastim-sndz, tbo-filgrastim, and pegfilgrastim. 30, 31 Filgrastim, filgrastim-sndz, and tbo-filgrastim should be administered at 5 mg/ kg/d until ANC recovery, whereas pegfilgrastim should be administered as a single dose of 6 mg per chemotherapy cycle. 30 Prophylactic antibiotics are not typically recommended for patients receiving standard-dose chemotherapy. 30 For patients who present with febrile neutropenia, prophylactic G-CSFs should be continued, and initiation of G-CSFs should be considered in patients who were not receiving G-CSFs prophylactically but who have risk factors for an infection-associated complication. 30, 31 With respect to trifluridine/tipiracil, G-CSF support was used in 9.4% of patients treated in the RECOURSE study and nearly 27% in patients treated at one of the major centers in Japan. 32 In patients with high-risk features, 30 ,31 G-CSFs should be started when the complete blood cell counts are known in day 15 and until the ANC increases to 2500/mm 3 .
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Anemia. A hemoglobin level 11 g/dL should elicit an anemia evaluation (Figure 2A) . 33 There are many potential etiologies of anemia in patients with mCRC, including hemorrhage and nutritional deficiencies. Other conditions that might contribute to the development of anemia should be identified and managed appropriately. 33 Red blood cell transfusion is the recommended treatment for patients with symptomatic anemia due to myelosuppressive chemotherapy, and the use of transfusions should also be considered for asymptomatic patients with anemia who have underlying comorbidities, such as coronary artery disease or chronic pulmonary disease, or for those who are considered high risk. 33 Thrombocytopenia. For platelet counts < 50,000/mm 3 , the dose of trifluridine/tipiracil should be held until the platelet counts increase to 75,000/mm 3 ( Figure 2A) . 11 If the delay is longer than 1 week, the dose of trifluridine/tipiracil in the next cycle should be reduced by 5 mg/m 2 per dose from the previous dose level (Table 3) . 11 Prophylactic platelet transfusions are recommended at a threshold platelet count of 10,000/mm 3 for patients with solid tumors who have chemotherapy-induced thrombocytopenia. 34 
Nonhematologic AEs
In the RECOURSE trial, hematologic AEs as well as nausea, diarrhea, vomiting, decreased appetite, and fatigue were most commonly observed in the TAS-102 group (Table 2) . 10 The trifluridine/tipiracil group had higher rates of Grade 3 nausea (2% vs. 1%), vomiting (2% vs. < 1%), and diarrhea (3% vs. < 1%). 10 However, there were no clinically meaningful differences between the treatment groups in the percentage of patients with other nonhematologic AEs, including decreased appetite, stomatitis, and hand-foot syndrome. 10 For Grade 3 nonhematologic AEs, the dose of trifluridine/tipiracil should be held until resolution of the AE to Grade 0 or 1 ( Figure 2B ). 11 With the exception of Grade 3 nausea, vomiting, or diarrhea that is controlled by medication, the dose of trifluridine/tipiracil in the next cycle should be reduced by 5 mg/m 2 per dose from the previous dose level for Grade 3 nonhematologic AEs (Table 3) .
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Nausea and Vomiting. Chemotherapy-induced nausea and vomiting might have a substantial effect on a patient's quality of life, treatment compliance, and health status. 35 The goal of antiemetic therapy is to prevent the onset of nausea and vomiting, and it is important for patients to continue receiving antiemetic therapy until 2 to 3 days after the last dose of chemotherapy (when the risk of nausea and vomiting has subsided). 35 Recommendations for antiemetic therapy are on the basis of the emetogenic risk of the chemotherapy agents as well as the patient's previous experience and other patient factors. 35, 36 Trifluridine/tipiracil is classified as having moderate to high emetic risk. 35 In the RECOURSE trial, the trifluridine/tipiracil group had higher rates of severe (Grade 3) nausea (2% vs. 1%) and vomiting (2% vs. < 1%) than the placebo group. 10 The incidence of nausea and vomiting (any grade) in patients receiving trifluridine/tipiracil was 48% and 28%, respectively. 10 For oral chemotherapy of moderate to high emetic risk, a 5-hydroxytriptamine 3 antagonist should be administered prophylactically (either dolasetron 100 mg/d orally, granisetron 1-2 mg/ d orally, granisetron 3.1 mg/d transdermal patch, or ondansetron 16-24 mg/d orally; Figure 2B ). 35 A benzodiazepine (lorazepam 0.5-2 mg orally, intravenously [I.V.], or sublingually every 6 hours as needed during the first 4 days) and/or an H 2 blocker or proton pump inhibitor may also be used as adjuncts. 35 Breakthrough emesis should be treated by adding a new antiemetic agent from a different class, such as a corticosteroid (dexamethasone), a cannabinoid (dronabinol or nabilone), a benzodiazepine (lorazepam or alprazolam), an atypical antipsychotic (olanzapine), or a phenothiazine (prochlorperazine or promethazine). 35, 36 After nausea and vomiting are controlled, treatment for breakthrough emesis should be administered on a prescribed schedule rather than an as-needed basis. 35 Patients who experience nausea might also derive benefit from specific dietary interventions, such as: eating smaller, more frequent meals; avoiding skipping meals; limiting liquids at meals; and eating foods at room temperature. 35 Some studies have shown that an increased protein intake might also help curb nausea. [37] [38] [39] Clinicians need to carefully assess nausea and vomiting throughout the entire course of treatment and determine whether the patient's antiemetic regimen is sufficient. 36 The cost of antiemetic treatment should also be discussed with patients, because its affordability might have an effect on compliance.
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Diarrhea. Diarrhea is a debilitating, potentially serious side effect that is commonly observed with other chemotherapy agents used in the treatment of mCRC, including 5-FU, capecitabine, irinotecan, and oxaliplatin, when combined with fluoropyrimidine chemotherapy. 40 The incidence of diarrhea (any grade) in patients who received trifluridine/tipiracil in the RECOURSE trial was 32% (3% Grade 3). 10 Diarrhea is categorized as either "uncomplicated"
(Grades 1 and 2) or "complicated" (Grades 3 and 4). 40 The initial management of Grade 1/2 diarrhea should include modifications to the patient's diet (small, frequent meals and elimination of lactose, alcohol, and high-osmolar supplements) and consultation with a registered dietician ( Figure 2B ). 40, 41 In general, for patients with Grade 1/2 diarrhea, treatment with the oral opiate loperamide hydrochloride is sufficient (4 mg initial dose followed by 2 mg every 4 hours, to a maximum of 16 mg/d) with or without diphenoxylate/ atropine (1-2 tablets of 2.5/0.025 mg orally 2-4 times per day, to a maximum of 8 tablets per day). 40 For patients with persistent, Grade 3/4 diarrhea and severe dehydration, it might be necessary to administer octreotide acetate, a somatostatin analogue (subcutaneously 100-150 mg 3 times per day or I.V. 25-50 mg/h) for the management of severe diarrhea and to achieve rapid control. 40 Intravenous fluids and treatment with an antibiotic such as a fluoroquinolone might also be required. 40 Whereas the incidence of severe diarrhea is relatively low with trifluridine/tipiracil, clinicians should pay close attention to patients' symptoms and provide early intervention with the treatment options discussed previously, if warranted.
Anorexia. The incidence of severe anorexia with trifluridine/tipiracil is relatively low (4% Grade 3 in the RECOURSE trial; 39% all Grades). 10 For patients who experience reduced appetite, appetite stimulants such as megestrol acetate (400-800 mg/d), dexamethasone (2-8 mg/d), or a cannabinoid should be considered ( Figure 2B ).
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There might also be superimposed psychological and/or emotional issues such as depression involved, and when appropriate, patients should be treated for these disorders; in the case of depression, mirtazapine (7.5-30 mg every bedtime) is recommended. 42 The treating oncologist should also attempt to identify and address any reversible conditions (such as oropharyngeal candidiasis) or symptoms (such as dysgeusia or fatigue) that might affect food intake and contribute to anorexia. 42 A nutritional consultation should be considered as should nutritional support, including liquid oral supplements as well as enteral or parenteral feeding. [42] [43] [44] Even mild anorexia might have a significant effect on a patient's quality of life and maintenance of appropriate body weight and might require timely intervention.
Fatigue. Although fatigue is commonly observed in patients with cancer, it is frequently underdiagnosed and undertreated. 45 The incidence of fatigue of any grade in patients receiving trifluridine/ tipiracil in the RECOURSE trial was 35% (4% Grade 3). 10 With this in mind, all patients should be regularly screened for fatigue during as well as after treatment. 45 In addition to medication side effects, numerous other factors might contribute to fatigue in patients with cancer, including emotional distress, anemia, sleep disturbances, nutritional problems, decreased functional status, drugdrug interactions, organ dysfunction, and other comorbidities. 45 If any of these other contributing factors is present, it should be treated appropriately ( Figure 2B ). 45 Patients currently receiving active treatment should use additional general intervention strategies, such as self-monitoring, energy conservation, diet, and distraction to manage their fatigue. 45, 46 Recommended nonpharmacologic interventions include physical activity, massage therapy, and psychosocial interventions. 45 If no other causes of fatigue have been identified, the use of psychostimulants, such as methylphenidate, might be considered. 45 It might also be helpful to address any nutritional and/or sleep issues. 45 
Conclusions
Trifluridine/tipiracil is a new treatment option for patients with mCRC who have been previously treated with 2 or more lines of standard chemotherapy, including previous fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, and, in patients with KRAS wild type tumors, an anti-EGFR antibody. The identification and effective management of adverse effects in patients receiving trifluridine/tipiracil are important. In particular, clinicians should be familiar with strategies to prevent and/or manage the increased incidence of myelosuppression that has been associated with trifluridine/tipiracil therapy. Moreover, communication with patients is an essential element in addressing other side effects such as nausea, vomiting, and fatigue. These strategies are critical because they might help patients continue therapy for a longer period of time, greatly facilitate patient adherence to therapy, and ultimately improve patients' quality of life and eventual clinical outcomes.
